Breaking News

Financial Report: Biogen Idec

April 23, 2014

51% growth driven by MS franchise

Biogen Idec
1Q Revenues:
$2.1 billion (+51%)

1Q Earnings: $480 million (+12%)

Comments: TECFIDERA, recently approved for MS patients in Europe, had revenues of $506 million, comprised of $460 million the U.S. and approximately $46 million outside the U.S. AVONEX revenues increased 2% to $761 million. TYSABRI revenues were up 41% to $441 million due to recording 100% its revenues following the acquisition of complete asset rights in 2Q13. RITUXAN and GAZYVA revenues from an unconsolidated joint business arrangement were $297 million.
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus